
CASSAVA SCIENCES INC — Investor Relations & Filings
Cassava Sciences, Inc. is a clinical-stage biotechnology company that develops investigational treatments for Central Nervous System (CNS) disorders. The company's primary focus is on its lead drug candidate, simufilam, a proprietary oral small molecule. Simufilam is designed to modulate the activity of the filamin A (FLNA) protein, which is involved in regulating neuronal development. The development program for simufilam targets conditions such as tuberous sclerosis complex (TSC)-related epilepsy and other mTOR pathway disorders. Preclinical studies in TSC models have shown that simufilam may reduce seizure frequency, supporting plans for future clinical trials.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | |
| 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | |
| 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-04-28 | English | |
| 8-K - CASSAVA SCIENCES INC (0001069530) (Filer) | 2026-02-19 | English | |
| FORM 8-K | 2025-12-23 | English | |
| FORM 8-K/A | 2025-12-22 | English |
Browse filings by year
21 years- 2026 4 filings
- 2025 50 filings
- 2024 68 filings
- 2023 53 filings
- 2022 38 filings
- 2021 34 filings
- 2020 48 filings
- 2019 43 filings
- 2018 52 filings
- 2017 42 filings
- 2016 33 filings
- 2015 37 filings
- 2014 53 filings
- 2013 50 filings
- 2012 42 filings
- 2011 56 filings
- 2010 76 filings
- 2009 60 filings
- 2008 50 filings
- 2007 85 filings
- 2006 30 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 43596105 | 10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | ||
| 42914481 | 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | ||
| 38155638 | 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-04-28 | English | ||
| 32886944 | 8-K - CASSAVA SCIENCES INC (0001069530) (Filer) | 2026-02-19 | English | ||
|
2025
11 filings
| |||||
| 11109579 | FORM 8-K | 2025-12-23 | English | ||
| 11109585 | FORM 8-K/A | 2025-12-22 | English | ||
| 11109591 | FORM 8-K | 2025-12-18 | English | ||
| 11109619 | FORM 8-K | 2025-12-17 | English | ||
| 11109593 | Regulatory Filings 2025 | 2025-12-08 | English | ||
| 11109595 | 424B2 | 2025-12-05 | English | ||
| 11109620 | FORM 8-K | 2025-12-03 | English | ||
| 11109618 | FORM 4 | 2025-11-25 | English | ||
| 11109599 | FORM 4 | 2025-11-24 | English | ||
| 11109601 | FORM 4 | 2025-11-20 | English | ||
| 11109622 | S-3 | 2025-11-13 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ovation Science Inc.
Develops and licenses patented Invisicare® technology for e…
|
OVAT | CA | Professional, scientific and te… |
|
OXFORD BIODYNAMICS PLC
Develops and commercializes precision medicine tests for on…
|
OBD | GB | Professional, scientific and te… |
|
Oxurion NV
Acquires majority stakes in European pharmaceutical subcont…
|
OXUR | BE | Professional, scientific and te… |
|
PACIFIC EDGE LIMITED
Develops non-invasive molecular tests for bladder cancer de…
|
PEB | NZ | Professional, scientific and te… |
|
PARADIGM BIOPHARMACEUTICALS LIMITED..
Repurposing PPS for osteoarthritis and rare inflammatory di…
|
PAR | AU | Professional, scientific and te… |
|
Pasithea Therapeutics Corp.
Develops treatments for central nervous system disorders, R…
|
KTTA | US | Professional, scientific and te… |
|
Passage BIO, Inc.
A clinical-stage genetic medicines company developing thera…
|
PASG | US | Professional, scientific and te… |
|
PATRYS LIMITED
Develops Deoxymab antibody therapies targeting DNA repair m…
|
PAB | AU | Professional, scientific and te… |
|
PAVmed Inc.
A diversified medical technology company developing devices…
|
PAVM | US | Professional, scientific and te… |
|
PegBio Co., Ltd.
Specializes in discovering and developing innovative therap…
|
2565 | HK | Professional, scientific and te… |
CASSAVA SCIENCES INC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33903/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33903 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33903 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33903 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33903}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CASSAVA SCIENCES INC (id: 33903)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.